AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 272: E989-E996, 1997;
0193-1849/97 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshimoto, T.
Right arrow Articles by Demura, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshimoto, T.
Right arrow Articles by Demura, H.

AJP - Endocrinology and Metabolism, Vol 272, Issue 6 E989-E996, Copyright © 1997 by American Physiological Society

ARTICLES

Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats

T. Yoshimoto, M. Naruse, M. Nishikawa, K. Naruse, A. Tanabe, T. Seki, T. Imaki, R. Demura, E. Aikawa and H. Demura
Department of Medicine, Tokyo Women's Medical College, Japan.

Although an improvement of insulin sensitivity has been shown to be a new therapeutic approach for treating diabetes mellitus, details of effects of this treatment on the cardiovascular system and possible renal complications remain unknown. In the present study, we investigated the effects of a thiazolidine derivative, pioglitazone, and examined the insulin-sensitizing action on blood pressure, nephropathy, and vascular changes in genetically obese diabetic Wistar fatty (WF) rats. Pioglitazone (3 mg.kg-1.day-1) was orally administered for 13 wk starting at the age of 5 wk, and the results were compared with those of vehicle-treated WF rats. At the age of 18 wk, vehicle-treated WF rats were associated with mild hypertension, nephropathy with proteinuria histological glomerular injury, and renal arteriolosclerosis in addition to hyperglycemia, hyperinsulinemia, and hyperlipidemia. Treatment with pioglitazone significantly improved glucose and lipid metabolism. In addition, it lowered blood pressure, decreased proteinuria, and prevented glomerular injury, renal arteriolosclerosis, and aortic medial wall thickening, whereas body weight, food intake, sodium balance, and urinary norepinephrine excretion were significantly increased. These results suggest that the insulin-sensitizing agent pioglitazone is effective in correcting not only glucose and lipid metabolism but also cardiovascular and renal complications in non-insulin-dependent diabetes mellitus.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
X. Ruan, F. Zheng, and Y. Guan
PPARs and the kidney in metabolic syndrome
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
P. Iglesias and J. J Diez
Peroxisome proliferator-activated receptor gamma agonists in renal disease.
Eur. J. Endocrinol., May 1, 2006; 154(5): 613 - 621.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
Y. Guan, Y. Zhang, A. Schneider, L. Davis, R. M. Breyer, and M. D. Breyer
Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature
Am J Physiol Renal Physiol, December 1, 2001; 281(6): F1036 - F1046.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online